Skip to main content


Full Schedule

Full Schedule

  • Thursday, October 14, 2021
  • 10:00 AM – 11:15 AM EDT
    New Drug Updates: Solid Tumors
  • 10:00 AM – 7:30 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Plan for Tomorrow Today, Managing patients with KRAS G12C-mutated NSCLC - Amgen Oncology
  • 12:15 PM – 1:00 PM EDT
    Herbal Medicine and Supplements: Friend or Foe?
  • 12:45 PM – 1:15 PM EDT
    Micro-Community Meet Ups
  • 12:45 PM – 1:30 PM EDT
    Moderated Clinical Posters
  • 1:30 PM – 2:15 PM EDT
    New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
  • 2:30 PM – 3:15 PM EDT
    PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement - Incyte Corporation
  • 3:30 PM – 4:15 PM EDT
    Survivorship Care Challenges: Navigating Changing Concerns
  • 4:30 PM – 5:15 PM EDT
    AML Patient Cases and Supporting Data - Bristol Myers Squibb
  • 5:30 PM – 6:45 PM EDT
    New Drug Updates: Solid Tumors
  • 6:45 PM – 7:30 PM EDT
    Herbal Medicine and Supplements: Friend or Foe?
  • 7:30 PM – 8:45 PM EDT
    Five Eyes: A Virtual Game Event